Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 multicenter, dose-escalation clinical study of the safety and tolerability of intravenously administered SNS-032 injection, a novel cyclin-dependent kinase inhibitor, administered to patients with advanced B-lymphoid malignancies

Next Previous
X
Search
Trial Profile

Phase 1 multicenter, dose-escalation clinical study of the safety and tolerability of intravenously administered SNS-032 injection, a novel cyclin-dependent kinase inhibitor, administered to patients with advanced B-lymphoid malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SNS 032 (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Sunesis Pharmaceuticals

    • Most Recent Events

    • 06 Jun 2012 Actual patient number changed from 40 to 21 as reported by ClinicalTrials.gov.
    • 19 May 2010 Status changed from active, no longer recruiting to completed, as results have been reported.
    • 19 May 2010 Results published online in Journal of Clinical Oncology, according to a media release from the John Theurer Cancer Center.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top